VERS.L Regulatory News (VERS)

Verseon Corporation

("Verseon" or the "Company")

Announcement of 2019 Annual General Meeting

FREMONT, Calif.-Verseon Corporation (AIM:VERS), the clinical-stage pharmaceutical company developing products and technologies to advance global health, today announces that its 2019 Annual General Meeting ("AGM") will be held on October 28, 2019, at 9 a.m. local time at the Critosphere Cowork Space, 7100 Stevenson Blvd. Fremont, CA 94538, USA.

At the AGM, the Company will seek shareholder approval for the following matters:

(a) Re-election of non-executive Class I Directors Dr. Thomas Hecht and Dr. Sangtae Kim

(b) The sale of the Company's headquarters

The Company seeks shareholder approval or ratification for the sale of its research, development, and operations facility located at 47071 Bayside Parkway, Fremont, California (the "Property") to provide working capital for the Company. Further details of the sale will be announced via RNS without delay once available in accordance with AIM Rules ahead of the AGM. If this is not possible, a separate notice of general meeting will be sent to shareholders to approve the sale of the Property and this building sale resolution will be withdrawn from the AGM.

(c) Such other business as may properly come before shareholders present, in person or by proxy

Copies of the 2019 AGM Proxy Information Statement are available to view and download between October 18 and October 28, 2019 from the Company's website at http://www.verseon.com/investor-notices/agm2019.

- Ends -

For further information, please contact

For trade and pharma media enquiries, please contact